The invalidation of claims 10-14 of the '731 patent removes a barrier to entry for competitors in the expandable spinal fusion device market. Monitor Globus's next earnings call for commentary on revenue impact and any plans to appeal or seek further patent protection. Competitors like Life Spine may now launch competing products, pressuring GMED's market share and pricing.
Price Chart
Executive Summary
The Federal Circuit reversed the PTAB's Final Written Decision, adopting Life Spine's broader construction of the claim term 'complementary with one another' to include mirrored angles. Under this construction, Globus conceded claims 10-14 of its '731 patent are obvious, rendering those claims unpatentable. This ruling removes a key patent from Globus's spinal implant portfolio, potentially exposing its expandable fusion devices to competition.
Court Ruling Details
Key Facts
- Federal Circuit reversed PTAB's Final Written Decision in IPR2022-01434, adopting Life Spine's claim construction for 'complementary with one another' to include mirrored angles.
- Claims 10-14 of Globus's U.S. Patent No. 8,845,731 ('731 patent) held unpatentable as obvious under the new construction.
- The '731 patent covers expandable fusion devices used in spinal surgery, a core product area for Globus.
- Globus made no argument for nonobviousness under Life Spine's construction, leading to reversal.
- The ruling is nonprecedential but binding on the parties.
Financial Impact
Loss of patent protection for expandable fusion device claims, potentially impacting a significant portion of Globus's spinal implant revenue. No damages awarded.
Risk Factors
- Increased competition from Life Spine and other rivals in expandable spinal fusion devices.
- Potential revenue erosion if Globus's expandable fusion devices lose market share or face price pressure.
- Possible further IPR challenges to other Globus patents in the same family.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-23o0yhd8-GMED |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Institutional Cluster | $81.66 | awaiting T+20 | — | $81.83 (+0.21%) |
Sep 15, 2026 5w ago | 144 | $74.69 $76.32 | ▲ +2.18% | ▼ −0.80% | $81.83 (+9.56%) |
Sep 11, 2026 6w ago | Court Ruling | $75.77 $76.24 | ▲ +0.62% | ▼ −1.64% | $81.83 (+8.00%) |
Aug 26, 2026 8w ago | Press Release | $82.54 $74.16 | ▼ −10.15% | ▼ −10.05% | $81.83 (−0.86%) |
Jul 16, 2026 14w ago | Press Release | $77.00 $85.90 | ▲ +11.56% | ▲ +7.11% | $81.83 (+6.27%) |
Jun 4, 2026 20w ago | 8-K | $80.00 $80.50 | ▲ +0.63% | ▼ −1.24% | $81.83 (+2.29%) |
Jun 4, 2026 20w ago | Court Ruling | $80.00 $80.12 | ▼ −0.15% | ▼ −1.52% | $81.83 (−2.29%) |
Apr 24, 2026 26w ago | DEFA14A | $93.70 $85.10 | ▼ −9.18% | ▼ −14.13% | $81.83 (−12.67%) |
Feb 24, 2026 34w ago | 8-K | $96.22 $87.35 | ▼ −9.22% | ▼ −3.98% | $81.83 (−14.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers